Find out more about how this website uses cookies to enhance your browsing experience.
Accept Cookies
On June 4, 2021, the FDA announced the long-awaited approval of Wegovy, a once-weekly injectable drug for weight loss.
In the months leading up to clearance, Wegovy received a lot of press, with a New York Times piece calling it a "game changer," MedPage Today reporting "extraordinary outcomes," and the BBC claiming it might usher in a "new era" in obesity treatment. Wegovy's efficacy has been lauded in the media as being superior to any other weight-loss medicine now on the market. Such spectacular headlines are typical in the media, so we must consider if all of the media attention is genuinely justified.
What exactly is Wegovy and how does it function?
Wegovy is the brand name for semaglutide, a high-dose injectable peptide hormone molecule that was previously approved by the FDA for the treatment of type 2 diabetes under the trade names Rybelsus (oral) and Ozempic (lower-dose injection).
The higher-dose Wegovy allows for the better crossing of the blood-brain barrier, which increases its weight-loss efficacy. Injectable semaglutide eliminates the strict guidelines for ingesting on an empty stomach required by oral semaglutide, while the higher-dose Wegovy allows for the better crossing of the blood-brain barrier, which increases its weight-loss efficacy.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonists or GLP-1 RAs, class of drugs. GLP-1 is a hormone that is produced naturally in the gastrointestinal tract in response to food intake. It has several effects, including boosting pancreatic insulin release, slowing stomach emptying, and reducing appetite through targeting brain receptors. This causes a feeling of satiety, or fullness, that lasts significantly longer than natural GLP-1 hormone levels.
Who will be able to take Wegovy?
Wegovy, like all other prescription drugs for the treatment of obesity, is licensed for use in those who have a BMI of 30 kg/m2 or higher.or those with a BMI of 27 kg/m2 and a weight-related medical condition such as hypertension, type 2 diabetes, or high cholesterol.
What are the disadvantages and advantages of Wegovy?
The STEP (Semaglutide Treatment Effect in People with Obesity) trials, Wegovy's phase 3 clinical trials, were undertaken in several clinical settings, each with modest differences in the study population and research design. The STEP 1 experiment, whose findings were published in the New England Journal of Medicine, found that those assigned to the pharmaceutical group lost an average of 14.9 percent of their body weight after 68 weeks of therapy, compared to only 2.4 percent for those assigned to the control group.
Nausea, diarrhea, vomiting, and constipation are the most common adverse effects of Wegovy. The prescription also comes with a warning about the possibility of a specific thyroid tumor, so it's not suggested for anyone who has a personal or family history of medullary thyroid cancer or type 2 multiple endocrine neoplasias (a genetic condition associated with endocrine tumors). It's worth noting that tumors were only seen in animal experiments and not in human trials.
How long do you think you'll be able to keep Wegovy?
Wegovy is one of six obesity drugs now approved by the FDA for long-term use.As a result, it can be used indefinitely as long as it is effective for weight loss and/or maintenance and does not cause unacceptable adverse effects. Exenatide was the first GLP-1 RA medicine to receive FDA approval in 2005;
since then, other GLP-1 RAs have been licensed and have undertaken long-term trials indicating either non-inferiority or superiority to placebo for major adverse cardiovascular events like heart attacks and stroke. The SELECT trial is a long-term cardiovascular outcomes trial for Wegovy that is underway and projected to be finished in September 2023.
Management of anti-obesity medications is changing.
Wegovy is the latest in a long line of drugs approved by the FDA for the treatment of obesity, beginning with phentermine in 1959. In the United States, phentermine, diethylpropion, benzphetamine, phendimetrazine, orlistat, phentermine/topiramate ER (Qsymia), bupropion/naltrexone (Contrave), liraglutide (Saxenda), setmelanotide (Imcivree), and recently semaglutide have all been authorized by the FDA (Wegovy).
Setmelanotide, it should be noted, is only licensed for the treatment of obesity caused by uncommon hereditary disorders. Metformin, zonisamide, and other GLP-1 RAs are commonly used to treat diabetes.
Many cases of therapeutics failing to demonstrate sufficient safety data to warrant FDA approval, such as rimonabant (Acomplia), or adverse effects necessitating market withdrawal, such as lorcaserin (Belviq), sibutramine (Meridia), dexfenfluramine (Redux), fenfluramine (Pondimin), and the infamous combination medic. Unfortunately, the rocky anti-obesity pharmaceutical landscape causes doctors to be hesitant to use the many safe and effective tools available today to treat obesity.
© 2024. All rights reserved.
On June 4, 2021, the FDA announced the long-awaited approval of Wegovy, a once-weekly injectable drug for weight loss.
In the months leading up to clearance, Wegovy received a lot of press, with a New York Times piece calling it a "game changer," MedPage Today reporting "extraordinary outcomes," and the BBC claiming it might usher in a "new era" in obesity treatment. Wegovy's efficacy has been lauded in the media as being superior to any other weight-loss medicine now on the market. Such spectacular headlines are typical in the media, so we must consider if all of the media attention is genuinely justified.
What exactly is Wegovy and how does it function?
Wegovy is the brand name for semaglutide, a high-dose injectable peptide hormone molecule that was previously approved by the FDA for the treatment of type 2 diabetes under the trade names Rybelsus (oral) and Ozempic (lower-dose injection).
The higher-dose Wegovy allows for the better crossing of the blood-brain barrier, which increases its weight-loss efficacy. Injectable semaglutide eliminates the strict guidelines for ingesting on an empty stomach required by oral semaglutide, while the higher-dose Wegovy allows for the better crossing of the blood-brain barrier, which increases its weight-loss efficacy.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonists or GLP-1 RAs, class of drugs. GLP-1 is a hormone that is produced naturally in the gastrointestinal tract in response to food intake. It has several effects, including boosting pancreatic insulin release, slowing stomach emptying, and reducing appetite through targeting brain receptors. This causes a feeling of satiety, or fullness, that lasts significantly longer than natural GLP-1 hormone levels.
Who will be able to take Wegovy?
Wegovy, like all other prescription drugs for the treatment of obesity, is licensed for use in those who have a BMI of 30 kg/m2 or higher.or those with a BMI of 27 kg/m2 and a weight-related medical condition such as hypertension, type 2 diabetes, or high cholesterol.
What are the disadvantages and advantages of Wegovy?
The STEP (Semaglutide Treatment Effect in People with Obesity) trials, Wegovy's phase 3 clinical trials, were undertaken in several clinical settings, each with modest differences in the study population and research design. The STEP 1 experiment, whose findings were published in the New England Journal of Medicine, found that those assigned to the pharmaceutical group lost an average of 14.9 percent of their body weight after 68 weeks of therapy, compared to only 2.4 percent for those assigned to the control group.
Nausea, diarrhea, vomiting, and constipation are the most common adverse effects of Wegovy. The prescription also comes with a warning about the possibility of a specific thyroid tumor, so it's not suggested for anyone who has a personal or family history of medullary thyroid cancer or type 2 multiple endocrine neoplasias (a genetic condition associated with endocrine tumors). It's worth noting that tumors were only seen in animal experiments and not in human trials.
How long do you think you'll be able to keep Wegovy?
Wegovy is one of six obesity drugs now approved by the FDA for long-term use.As a result, it can be used indefinitely as long as it is effective for weight loss and/or maintenance and does not cause unacceptable adverse effects. Exenatide was the first GLP-1 RA medicine to receive FDA approval in 2005;
since then, other GLP-1 RAs have been licensed and have undertaken long-term trials indicating either non-inferiority or superiority to placebo for major adverse cardiovascular events like heart attacks and stroke. The SELECT trial is a long-term cardiovascular outcomes trial for Wegovy that is underway and projected to be finished in September 2023.
Management of anti-obesity medications is changing.
Wegovy is the latest in a long line of drugs approved by the FDA for the treatment of obesity, beginning with phentermine in 1959. In the United States, phentermine, diethylpropion, benzphetamine, phendimetrazine, orlistat, phentermine/topiramate ER (Qsymia), bupropion/naltrexone (Contrave), liraglutide (Saxenda), setmelanotide (Imcivree), and recently semaglutide have all been authorized by the FDA (Wegovy).
Setmelanotide, it should be noted, is only licensed for the treatment of obesity caused by uncommon hereditary disorders. Metformin, zonisamide, and other GLP-1 RAs are commonly used to treat diabetes.
Many cases of therapeutics failing to demonstrate sufficient safety data to warrant FDA approval, such as rimonabant (Acomplia), or adverse effects necessitating market withdrawal, such as lorcaserin (Belviq), sibutramine (Meridia), dexfenfluramine (Redux), fenfluramine (Pondimin), and the infamous combination medic. Unfortunately, the rocky anti-obesity pharmaceutical landscape causes doctors to be hesitant to use the many safe and effective tools available today to treat obesity.
© 2024. All rights reserved.
Our aim is to offer better technology to healthcare providers who in turn can provide better care for the health seekers.
Just go to the S10.Clinic website and click on the "Book appointment" button on the homepage of the website/app, select a specialty and find the doctor of your choice. Once you select a doctor, you can click on the "Consult Online" button to select your preferred date and time.
Once you select the date and time all you have to do is sign up / login to the platform and make the payment online using your credit / debit card on the Razor pay or CC Avenue gateway. Then, you will receive the consultation link via sms / email.
Our online consultation platform is optimized for the following browsers: Google Chrome and Safari. Please ensure you are free 10 minutes prior to your appointment.
All you have to do is find a well light and quiet place with good internet connectivity, preferably a place with Wi-Fi access. Switch on your microphone (for laptop / mobile and allow browser to access it).
Please note: If you are not able to open the link please delete your browser history and cache files of your browser and try again.
This may happen due to poor internet connectivity. In such cases, please check your internet connection and if the issue persists, please reach out to us at onlineconsulting@s10.clinic with the screenshot of the error and we will get this checked from our end. You can also call us at 044-40510510.
Please note: Please ensure you have given access to your audio and video to your browser in the settings panel.
You will receive an email after the online consultation with the following - Provisional diagnosis, visit notes, prescription and follow up.
Yes. The prescription generated during the online consultation is as good as a physical prescription and will be valid for 6 months from the date of issue (as per government regulations).
You will be able to speak and interact with the doctor only for the time he has specified.
Yes. The e-prescription will be valid for offline pharmacies as well.
Safety of your data is our top priority. We have multi-level security checks, multiple data backups, and stringent policies in place to ensure your data remains safe and secure. Additionally, we are a HIPAA compliant company and we take data privacy and security very seriously. All data on S10.Clinic is secured with 256-bit encryption.
All the patients who use the S10.Clinic platform will be called and verified by our support squad before their consultation with the doctors.
You don't have to worry about it. In that case an automatic refund is initiated from our end, and it will reflect in your bank account within 6-7 business days.
Or you can reach out to us at 044-40510510 or onlineconsulting@s10.clinic and we will be happy to help you.
Don't worry if you've missed the online call with the, you can easily reschedule the call with your preferred doctor 10 minutes prior to any consultation. All you have to do is click on the "Reschedule" option in the appointment email.
Or you can reach out to us at 044-40510510 and we can book the same for you.
Please note: If you do not show up or miss an appointment after your appointment time, you won't be able to reschedule it.
You can reschedule any appointment you make 10 minutes before the consultation free of cost. If you want to reschedule any appointment after the consultation time has started you will have to book a new appointment with your preferred doctor. No refund will be offered in such cases.
After the online consultation you will receive a feedback form where you can rate your experience and tell us what went well, what we need to work on. We take your feedback very seriously and this helps us to improve our app and our services.
We're always there for you! You can reach out to our Support Squad at 044-40510510 or send us an email at onlineconsulting@s10.clinic. You can also dm us on Facebook we will be happy to assist you.
Comments